The cornerstone to Bicycle Therapeutics’ value proposition is its proprietary technology that enables the systematic cyclisation of peptides with variable loop sizes to generate large, diverse phage display libraries comprising more than 1012 unique Bicycles®. The platform combines the power of biological selection with the drug-like properties endowed by the constraint of a chemical scaffold. The company identifies Bicycles® by screening vast phage display libraries that present the peptides as cyclised molecules on the phage surface. Screening can be conducted against either isolated proteins or with whole cells expressing the target of interest. Bicycle Therapeutics has successfully identified high potency nanomolar hits against a variety of targets including cytokines, chemokines, a range of enzymes and proteases as well as cell surface receptors.